CharabatiMWheelerMAWeinerHL, et al. Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell2023; 186: 1309–1327.
2.
AbdelhakAFoschiMAbu-RumeilehS, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol2022; 18(3): 158–172.
3.
GreeneDNSchmidtRLWilsonAR, et al. Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: A test utilization study. Am J Clin Pathol2012; 138(2): 262–272.
4.
KalluriRMcAndrewsKM. The role of extracellular vesicles in cancer. Cell2023; 186: 1610–1626.
5.
SoleymaniTChenTYGonzalez-KozlovaE, et al. The human neurosecretome: Extracellular vesicles and particles (EVPs) of the brain for intercellular communication, therapy, and liquid-biopsy applications. Front Mol Biosci2023; 10: 1156821.
6.
SelmajICichalewskaMNamiecinskaM, et al. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol2017; 81(5): 703–717.
7.
GillAJSchorrEMGadaniSP, et al. Emerging imaging and liquid biomarkers in multiple sclerosis. Eur J Immunol2023; 53(8): e2250228.
8.
SurappaSMultaniPParlatanU, et al. Integrated “lab-on-a-chip” microfluidic systems for isolation, enrichment, and analysis of cancer biomarkers. Lab Chip2023; 23: 2942–2958.
9.
GalazkaGMyckoMPSelmajI, et al. Multiple sclerosis: Serum-derived exosomes express myelin proteins. Mult Scler2018; 24(4): 449–458.
10.
AgliardiCGueriniFRZanzotteraM, et al. Myelin basic protein in oligodendrocyte-derived extracellular vesicles as a diagnostic and prognostic biomarker in multiple sclerosis: A pilot study. Int J Mol Sci2023; 24: 894.
